An Australian stem cell and regenerative medicine company

ASX Announcements

06 Oct 2020 Date of AGM & Closing Date for Director Nominations
24 Sep 2020 Potential Utility of Cymerus MSCs in Heart Attack Model
15 Sep 2020 Cynata Clinical Trial Results Published in Nature Medicine
14 Sep 2020 Appendix 3G
07 Sep 2020 Cymerus MSCs Effective in Preclinical Lung Disease Study
25 Aug 2020 Appendix 4E & Annual Report
24 Aug 2020 Patient Enrolment Opens in COVID-19 Clinical Trial
19 Aug 2020 Appendix 3G
18 Aug 2020 Cynata Appoints Dr Geoff Brooke as Chairman
14 Aug 2020 Cynata Investor Presentation
07 Aug 2020 Notice of Allowance from Korean Patent Office
05 Aug 2020 Notification of Expiry of Unlisted Options
30 Jul 2020 Cynata Announces Positive Results from GvHD Trial Follow-up
28 Jul 2020 Quarterly Activity Report & Appendix 4C
20 Jul 2020 Notification of Expiry of Unlisted Options
01 Jul 2020 Securities Dealing Policy
01 Jul 2020 Final Director's Interest Notice
24 Jun 2020 Appendix 3Y-Dr Geoff Brooke
18 Jun 2020 Ethics Approval & Expedited Pathway for Phase 3 OA Trial
16 Jun 2020 Appendix 3X-Darryl Maher
16 Jun 2020 Appendix 3Y-Ross Macdonald
16 Jun 2020 Appendix 3Y-Stewart Washer
16 Jun 2020 Dr Darryl Maher joins Cynata Board
16 Jun 2020 Block Trade Proceeds to Reduce Director Loans
10 Jun 2020 Appendix 2A
10 Jun 2020 Investor Presentation
02 Jun 2020 Appendix 2A
27 May 2020 Cynata Successfully Completes Share Purchase Plan
08 May 2020 Ethics Approval to Commence Clinical Trial in COVID-19
01 May 2020 Cleansing Notice
01 May 2020 Appendix 2A
30 Apr 2020 Share Purchase Plan Booklet
24 Apr 2020 Cleansing Notice
24 Apr 2020 Appendix 2A
24 Apr 2020 Quarterly Activity Report & Appendix 4C
22 Apr 2020 Cynata Announces $5.55m capital raising
22 Apr 2020 Proposed Issue of Securities
20 Apr 2020 Trading Halt
17 Apr 2020 Cynata MSCs beneficial in preclinical ARDS study
01 Apr 2020 Cynata provides guidance on planned clinical trials
11 Mar 2020 Market Update & Additional A$618k R&D Tax Refund
10 Mar 2020 Cynata Receives Japan Patent Notice of Allowance
03 Mar 2020 Canadian Patent Issued for CYP Unique Stem Cell Technology
20 Feb 2020 Appendix 4D & Half-Year Financial Statements
06 Feb 2020 Notice of Allowance from Israel Patent Office
31 Jan 2020 Cynata Investor Presentation
30 Jan 2020 December 2019 Quarterly Report
14 Jan 2020 Cynata Receives UK Regulatory Approval for CLI Trial
07 Jan 2020 Cynata Receives $1.892m R&D Tax Incentive Refund
16 Dec 2019 Appendix 3Y-Dr Paul Wotton